...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis
【24h】

Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis

机译：苯扎贝特和熊去氧胆酸联合治疗原发性胆汁性肝硬化的Meta分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to assess the efficiency and safety of combination therapy of ursodeoxycholic acid (UDCA) and bezafibrate for primary biliary cirrhosis. A meta-analysis of all long-term randomized controlled trials comparing the combination of UDCA and bezafibrate with UDCA monotherapy was performed via electronic searches. Seven trials, which included 177 patients, were assessed. Combination therapy with UDCA and bezafibrate was more effective than UDCA monotherapy in improving liver biochemistry, alkaline phosphatase (mean difference [MD], -146.15 IU/L; 95% confidence interval [CI], -193.58 to -98.72; P < 0.00001), gamma-glutamyltransferase (MD, -20.64 IU/L; 95% CI, -30.86 to -10.43; P < 0.0001), immunoglobulin M (MD, -90.96 mg/dL; 95% CI, -137.36 to -44.56; P = 0.0001) and triglycerides (MD, -15.49 mg/dL; 95% CI, -30.25 to -0.74; P = 0.04). However, their effects on pruritus (odds ratio [OR], 0.82; 95% CI, 0.30-2.24; P = 0.70) and alanine aminotransferase (MD, -8.41 IU/L; 95% CI, -22.57 to 5.75; P = 0.24) did not differ significantly. This meta-analysis revealed no significant differences in the incidence of all-cause mortality (OR, 0.72; 95% CI, 0.10-5.49; P = 0.75) and adverse events (OR, 0.35; 95% CI, 0.07-1.84; P = 0.22) between patients treated with combination therapy and those treated with monotherapy. In this meta-analysis, combination therapy with UDCA and bezafibrate was more effective than UDCA monotherapy. Combination therapy improved liver biochemistry, but did not improve clinical symptoms, incidence of death or adverse events more effectively than monotherapy.
机译：这项研究的目的是评估熊去氧胆酸（UDCA）和苯扎贝特联合治疗原发性胆汁性肝硬化的效率和安全性。通过电子检索对所有比较UDCA和苯扎贝特联合UDCA单药治疗的长期随机对照试验进行荟萃分析。评估了包括177名患者在内的七项试验。 UDCA和苯扎贝特联合治疗在改善肝脏生物化学，碱性磷酸酶方面优于UDCA单药治疗（平均差[MD]，-146.15 IU / L; 95％置信区间[CI]，-193.58至-98.72; P <0.00001） ，γ-谷氨酰转移酶（MD，-20.64 IU / L; 95％CI，-30.86至-10.43; P <0.0001），免疫球蛋白M（MD，-90.96 mg / dL; 95％CI，-137.36至-44.56; P ＝ 0.0001）和甘油三酸酯（MD，-15.49mg / dL; 95％CI，-30.25至-0.74; P ＝ 0.04）。然而，它们对瘙痒的影响（比值[OR]为0.82; 95％CI为0.30-2.24; P = 0.70）和丙氨酸转氨酶（MD为-8.41 IU / L; 95％CI为-22.57至5.75; P = 0.24）没有显着差异。这项荟萃分析显示，全因死亡率（OR，0.72; 95％CI，0.10-5.49; P = 0.75）和不良事件（OR，0.35; 95％CI，0.07-1.84; P = 0.22）在接受联合治疗的患者和接受单一治疗的患者之间。在这项荟萃分析中，UDCA和苯扎贝特联合治疗比UDCA单药治疗更有效。联合疗法比单一疗法更有效地改善了肝脏的生化特性，但没有改善临床症状，死亡或不良事件的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号